Healthcare
We offer a broad portfolio of solutions on large-scale protein production for both human healthcare and veterinary applications, such as mass vaccination and diagnostics kits.
Algenex SL has been recognised as the best European company in the Animal Health Awards 2021 by IHS Markit Agribusiness.
Algenex has more than 20 years’ experience in the veterinary sector and is focused on developing and producing veterinary vaccines using its TopBac® and CrisBio® technology platforms.
We have successfully produced more than 200 molecules in collaboration with public and private partners, including multiple international pharmaceutical companies and achieved proof-of- concept in more than 20 indications across most livestock species.
FatrovaxRHD, first vaccine produced in CrisBio® received marketing authorization in the European Union and United Kingdom in Q3.
Benefits of using CrisBio® in the production of proteins for veterinary vaccines:
-
Linear scalability
-
Reduced production costs
-
Increased productivity, reaching gram per litre yields
Most advanced projects in animal health
RHDV
PCV2
BVD
INFLUENZA
H7N9
African Swine Fever
AB rapid detection test
Partnerships
Algenex has a long track record of successful collaborations with public and private partners on a global scale. Customer satisfaction is one of our top priorities
”
For us, CrisBio® technology represents an important opportunity to expand its portfolio of vaccines for veterinary use with a series of highly innovative products
DIAGNOSTICS
Herdscreen® ASFV, developed jointly between Algenex and GlobalDX, is a point-of-care rapid diagnostic test that identifies animals which have been exposed to the African Swine Fever Virus (ASFV) using whole blood, plasma or serum samples. Herdscreen® uses a highly specific antigen produced using CrisBio®.
This antigen is able to capture antibodies developed during infection with ASFV with 100% specificity and higher sensitivity than a commercial ELISA test, as evidenced in field and experimental samples from infected animals gathered by the European Union Reference Laboratory for African Swine Fever (CISA-INIA).
Herdscreen® ASFV been on the market since 2021. The test is being increasingly adopted by food and meat industry to contribute to certifying the ASFV-infection status through the entire supply chain and as a consequence help reducing disease spread.
CrisBio® applications in OneHealth
Prevention of infectious diseases in animals
Up to 75% of new diseases affecting people over the past 10 years originated in animals 13 zoonoses are responsible for 2.2 million deaths per year.
Pandemic preparedness
Requiring rapid response and production scale-up.
Universal access to biotech products
Simple production process at significantly lower cost allows commercial viability of biotech product in developing economies.
Most advanced projects in human health
INFLUENZA
H1N1; H7N9; H5N1
CoV-19
HPV
Anti Human rotavirus VP6
VACCINES
Algenex has completed a proof of concept study in avian influenza, a zoonotic disease that has the potential to turn into a global pandemic. In this study, Algenex demonstrated its ability to develop a fully functional and safe vaccine in only four months.
Using CrisBio®, Algenex is ideally positioned to produce and supply large quantities of proteins to pharmaceutical companies developing and manufacturing vaccines quickly and at competitive prices. This would enable widespread immunization, in particular in countries with weak economies and less advanced public health systems.
DIAGNOSTICS
Algenex has licensed its CrisBio® technology to Biokit (Werfen Group), who is commercializing two diagnostic kits for human applications based on Algenex’ technologies.
